Objective To assess the safety and efficacy of novel pulsed field ablation (PFA) as a treatment option for atrial fibrillation. Methods and results PubMed, Ovid, Google Scholar, Web of Science, and Scopus databases and various major scientific conferences were searched for studies reporting outcomes about pulsed-field ablation technique. Sixteen studies were included reporting 485 with atrial fibrillation who underwent pulsed field operation. Most of the patients had an average age of 60 years. Their total procedure time was 94 min. Their mean time of Fluoro procedure is 17 min. The overall proportion of successful pulmonary vein isolation is 100% with 95% CI (p =1.00). The overall recurrence rate of arrhythmia in the participants is 0.0284 with 95%-CI (p =0.79). During or after the PFA surgery, the overall proportion of complications was 0.0223 (p <0.01) with 95%-CI indicating high safety of the PFA procedure. Conclusion The novel technique of pulsed-field ablation has shown very safe outcomes and high efficacy as a novel treatment for patients with atrial fibrillation

Most instances of Guillain-Barré syndrome (GBS) are caused by immunological stimulation and are discovered after vaccinations for tetanus toxoid, oral polio, and swine influenza. This systematic study investigated GBS cases reported after receiving the COVID-19 vaccination.

Here we report a patient with 2q37 deletion syndrome confirmed by comparative genomic hybridization (CGH) plus single nucleotide polymorphism (SNP), who does not suffer from mental developmental abnormalities. The patient, however, does suffer from fatigue and gross motor delay, and the presence of a patent foramen ovale.